$AVR

L1 Capital Pty Ltd sold $1.4M of AVR (indirect holdings)

L1 Capital Pty Ltd sold 174,721 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at $8.10 ($1.42M total) on 2026-08-06.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Aug 10, 2026, 11:24 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 11:38 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

A 10% owner sold about $1.42M of AVR shares at $8.10/share; the filing does not cite a 10b5-1 plan and provides post-transaction holdings.

02

Market read

Traders may monitor for follow-on selling or interpret the sale as sentiment, but there is no new operational or financial catalyst for AVR in the text.

03

What to watch

The transaction is indirect and lacks stated rationale; absence of a cited 10b5-1 plan does not confirm opportunistic selling, and the holder still retains 5.439M shares after the sale.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-10 for a sale dated 2026-08-06

Background

The article is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp. (AVR).

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd, a 10% owner, sold 174,721 AVR shares in an open-market transaction for about $1.42M, filed as a Form 4.

Expected impact

Likely limited near-term impact; could add mild overhang if investors interpret it as reduced conviction, but it is not a company fundamental change.

Evidence & confidence

Form 4 insider sales can be routine and do not necessarily signal fundamentals. The filing provides transaction size, price ($8.10), and post-sale holdings (5.439M), but no accompanying company news or guidance change.

Market effects

No sector read-through; this is a single-issuer insider transaction.

None indicated.

None indicated.

Counterpoint

The sale may be liquidity-driven or part of pre-planned diversification, especially since the filing does not provide a clear motive.

Key entities

  • Anteris Technologies Global Corp.

    Subject of the Form 4 insider transaction disclosure (AVR).

  • L1 Capital Pty Ltd

    Reporter of the indirect open-market sale of AVR shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.